Advanced Therapies Integrates 2021 Track 1
TRENDING TECHNOLOGY
Welcome and opening remarks
SHARON BROWNLOW | Chief Business Officer | Cell and Gene Therapy Catapult
Navigating the regulatory maze
Cell and gene therapies raise specific challenges to securing regulatory approvals. This session will look in detail at those challenges and provide insight into effective regulatory strategies.
FACILITATED BY
JAMES FRY | Partner and Head of Life Sciences | Mills & Reeve
PANELLISTS INCLUDE
AHMED BOUZIDI | Vice-President Biotech | ProductLife Group
AGATHE GUILLOT | Head of Regulatory Affairs | Cell and Gene Therapy Catapult
MARIAN REVIRIEGO | Executive Regulatory Consultant & Co-Founder | Alladvice
LEE CONEY | Head of Non-Clinical Safety | Cell and Gene Therapy Catapult
ELIZABETH FAIRLEY | Chief Operating Officer | Talking Medicines
Britain’s Talent for technology
Do we have the right skills and capabilities in place to identify and develop the next generation of ATMPs?
FACILITATED BY
JAMES STRACHAN | Editor | The Cell + Gene Curator
PANELLISTS INCLUDE
NICK STEPHENS | Executive Chairman | The RSA Group
CHRIS NOWERS | Chief Executive Officer | ONK Therapeutics
CHARLOTTE CASEBOURNE | Chief Executive Officer and Co-founder | Theolytics
STEPHEN WARD | Chief Manufacturing Officer| Cell and Gene Therapy Catapult
COLIN MACKAY | Founder and CEO | Symbiosis Pharmaceutical Services Ltd
Getting to Market
A Discussion on Challenges, Opportunities and Market Access within Advanced Therapies; how do we create a robust market economy for Advanced therapies, taking into account costs of goods, manufacture and procurement. Do we need a new business model?
FACILITATED BY
MARTINO PICARDO | Chairman | Discovery Park
PANELLISTS INCLUDE
KATE COLEMAN | Senior Director and Principal Consultant | PharmaLex
KEITH FOSTER | Chief Science Officer | Sutura Therapeutics
KATE ROWLEY | Venture Partner | Global Bio Fund
Fast Forward
What are the emerging therapeutic technologies and what will the next generation of ATMPs look like? Do we have the right technologies & capabilities to develop and manufacture them?
FACILITATED BY
JESÚS ZURDO | Global Head Cell, Gene Therapy & Bioproduction | Horizon Discovery
PANELLISTS INCLUDE
JANE THEAKER | Chief Executive Officer | Kinomica
JOE HEALY | Chief Executive Officer and Co-Founder | NanoSyrinx
BAKUL GUPTA | Chief Executive Officer and Co-founder | ImmTune Therapies
TIM LUKER | Vice President Emerging Technology and Innovation | Eli Lilly
RANJEEVA RANASINGHE |Product Director, Cell and Gene Therapy | GSK
Closing Remarks
SHARON BROWNLOW | Chief Business Officer | Cell and Gene Therapy Catapult